Company / Accounts Receivable
BIOCRYST PHARMACEUTICALS INC Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$106.8M
FY2025
5-year range
$29.4M / $106.8M
FY2021-FY2025
Trend
+35.1%
vs FY2024
Sector context
#54 of 115
Health Care
What the data says
At $107M, BIOCRYST PHARMACEUTICALS INC's accounts receivable ranks #54 of 115 in the Health Care sector. Accounts Receivable has increased for 5 consecutive years, from $9M in FY2020 to $107M in FY2025.
Based on SEC 10-K filings.
$107M in FY2025 with a 5-year CAGR of +65.3%.
Improved from $57M to $107M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +28.3%
- 5-Year CAGR
- +65.3%
- 10-Year CAGR
- -
Sector benchmark
#54 of 115 in Health CareTop 47% of 115This company $106.8M Sector average $1.1B
▼
-90.4% below sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's accounts receivable has grown for 5 consecutive years.
- 5-year CAGR of +65.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 35.1% year-over-year.
- Ranks #54 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $106.8M | +35.1% |
| FY2024 | $79.1M | +38.8% |
| FY2023 | $57.0M | +12.6% |
| FY2022 | $50.6M | +72.0% |
| FY2021 | $29.4M | +240.2% |
| FY2020 | $8.6M | -61.0% |
| FY2019 | $22.1M | +415.9% |
| FY2018 | $4.3M | -29.8% |
| FY2017 | $6.1M | -30.2% |
| FY2016 | $8.8M | +40.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026